Literature DB >> 24346640

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

Nathan Clumeck1, Jean-Michel Molina, Keith Henry, Joseph Gathe, Jürgen K Rockstroh, Edwin DeJesus, Xuelian Wei, Kirsten White, Marshall W Fordyce, Martin S Rhee, Javier Szwarcberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24346640     DOI： 10.1097/QAI.0000000000000089

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  21 in total

1.  Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.

Authors:  Kristen N Andreatta; Derrick D Goodman; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

Review 2.  Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

Authors:  R Martin-Iguacel; J M Llibre; N Friis-Moller
Journal:  Curr HIV/AIDS Rep       Date:  2015-12       Impact factor: 5.071

Review 3.  A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection.

Authors:  Alexa Vyain Zhao; Rustin D Crutchley; Rakesh Chowdary Guduru; Kathy Ton; Tammie Lam; Amy Cheng Min
Journal:  Retrovirology       Date:  2022-10-22       Impact factor: 3.768

4.  The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.

Authors:  Rima Kulkarni; Rebecca Hluhanich; Damian M McColl; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

5.  Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.

Authors:  Kristen N Andreatta; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

Review 6.  Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.

Authors:  Walter Dehority; Jacobo Abadi; Andrew Wiznia; Rolando M Viani
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

Review 7.  Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence.

Authors:  Thibault Mesplède; Mark A Wainberg
Journal:  Viruses       Date:  2015-07-07       Impact factor: 5.048

Review 8.  Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.

Authors:  Sandrine Cure; Florence Bianic; Caroline Espinas; Helene Hardy; Lisa Rosenblatt; Timothy Juday
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

Review 9.  HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety.

Authors:  Kimberly K Scarsi; Joshua P Havens; Anthony T Podany; Sean N Avedissian; Courtney V Fletcher
Journal:  Drugs       Date:  2020-11       Impact factor: 9.546

Review 10.  Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS.

Authors:  Roberta Prinapori; Antonio Di Biagio
Journal:  Patient Prefer Adherence       Date:  2015-08-24       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.